Frontiers in Psychiatry
2021
Georgios Mikellides, Panayiota Michael, Lilia Psalta et al.
17 citations
Depression is a common mental disorder that affects many people worldwide, while a significant proportion of patients remain non-responsive to antidepressant medications. Alternative treatment options such as ketamine therapy and repetitive transcranial magnetic stimulation (rTMS) therapy are offered nowadays. This study aims to describe and compare the acute antidepressive efficacy of both,...
Revista Colombiana de psiquiatria
2021
Raul Felipe Palma-álvarez, Lara Grau-López, Elena Ros-Cucurull et al.
12 citations
Ayahuasca is a psychotropic infusion prepared by boiling the bark of Amazonian plants and has many psychopharmacological effects not fully understood. Some of those effects are used as treatment for different diseases. However, the side effects of ayahuasca, including ayahuasca-induced psychosis, are an important issue. Here we report the case of a patient who had a psychotic episode after...
Advances in experimental medicine and biology
2021
José Carlos Bouso, Genís Ona, Rafael G. Dos Santos et al.
6 citations
The volume of research on the therapeutic use of psychedelic drugs has been increasing during the last decades. Partly because of the need of innovative treatments in psychiatry, several studies have assessed the safety and efficacy of drugs like psilocybin or ayahuasca for a wide range of mental disorders, including major depression. The first section of this chapter will offer an introduction...
Psychotherapy and Psychosomatics
2021
Samuel t. Wilkinson, Taeho greg Rhee, Jutta Joormann et al.
102 citations
<b><i>Introduction:</i></b> Ketamine has emerged as a rapid-acting antidepressant. While ongoing treatment can prevent relapse, concerns exist regarding long-term exposure. <b><i>Objective:</i></b> We conducted a randomized trial to examine the feasibility and efficacy of cognitive behavioral therapy (CBT) following intravenous ketamine in treatment-resistant depression (TRD)....
International Journal of Advanced Research in Medicine
2021
Yogesh Kumar Chahar
Major depressive disorder (MDD) has become a health crisis of epidemic proportions in the modern world. One in six individuals in the world is experiencing an episode of major depression in his or her lifetime, and it is estimated that major depression will rank second after cardiac disease as a cause of international medical morbidity by the year 2020. Depression is associated with greater...
Brazilian Journal of Development
2021
Vagner Fagnani Linartevichi, Matheus Gonzales Froza, Rafael de Morais Cury et al.
4 citations
A depressão, ou Distúrbio Depressivo Maior (DDM), é uma enfermidade que acomete cerca de 322 milhões de pessoas e pode ser debilitante, havendo uma grande demanda para tratamentos eficazes no manejo desta doença. O presente estudo teve por objetivo organizar uma revisão de artigos publicados acerca do uso do composto psilocibina, a fim de averiguar seu potencial terapêutico no tratamento de...
Porto Biomedical Journal
2021
Henrique Castro Santos, João Gama Marques
37 citations
Abstract Background: Psilocybin is a predominant agonist of 5HT 1A and 5HT 2A/C receptors and was first isolated in 1958, shortly before it became a controlled substance. Research on the potential therapeutic effects of this compound has recently re-emerged alongside what is being addressed as a psychedelic renaissance. Methods: In this paper we performed a systematic review of the clinical...